logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Immuno-oncology—disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it—took center stage in the drug development world in 2014. Stephen Dunn of LifeTech Capital believes that preeminence will continue in 2015, bolstered by new drug approvals, new targets and new combination immunotherapies that…
Read more...
Flashback Photobomber Hoodie If you read my recent article Wearable Cameras, you understand that video embedded in clothing is on the horizon and the "point and shoot" camera phone will not be how most photo and video content will be created. Instead, it will be created from someone's hat, or…
Read more...
Biotechnology indices have been on a rapid ascent for three years, and 2015 appears to be off to the races as well. Bloom Burton & Co.'s David Martin has taken his seat in the grandstands, betting on specialty pharma and biotech companies based in Canada, where resource stocks have absorbed…
Read more...
The marijuana industry is one with great promise…and relative uncertainty. Navigating the ever-changing regulatory environment is often fraught with difficulties, making it difficult to do the sort of long-term planning that most businesses rely on. However, some companies have found a middle-path, one that leverages the medical benefits of marijuana…
Read more...
Andrew McDonald believes investors fundamentally underestimate the risk of investing in companies with drugs in development. To address the inherent hazards, McDonald cofounded LifeSci Advisors, which creates exchange-traded funds to limit risk. In this interview with The Life Sciences Report, McDonald describes how funds can be designed to grow on…
Read more...
Invitae (NVTA) is on a mission to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. It is based in San Francisco, CA. Six other companies are scheduled for the week of Feb. 9, 2015. The full IPO calendar is available…
Read more...
For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into…
Read more...
Only fifteen years ago, I was still a diligent hi-tech employee with no clue about the markets. All I knew was that loads of money shifted there, and I was determined to get my hands on some of it. My first problem, which everyone wishing to succeed must face, was:…
Read more...
Recently, equities.com had the opportunity to speak with Jack Brewer of The Brewer Group to learn about the upcoming TBG Innovations Conference on February 9 at the Mondrian South Beach in Miami, Florida. One of the more exciting companies set to present and showcase their innovative work is BioRestorative Therapies…
Read more...
   ↵ At equities.com, we’ve always been focused on building an active community among the leading voices within the world of finance. As with many other fields, in finance, we’ve noticed a significant shift away from traditional sources of financial news, tips and predictions, and toward a growing number of…
Read more...
At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond. The experts also sent investors who attended the panel discussion of The Life Sciences Report's 2015 Small-Cap…
Read more...
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. But realistically assessing the therapeutic potential of pipeline products is the healthy approach for selecting a winner. In this interview with The Life Sciences Report, Edward Stopke of Sagient Research unveils…
Read more...
Page 1 of 49

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.